


CURAPATH

Your CDMO Partner for Drug Delivery Programs

Spring 2025

ACCELERATE YOUR NON-VIRAL DELIVERY PHARMACEUTICAL DEVELOPMENT


Novel Polymer & Lipid Excipients

Manufacturing of Lipid, Polymers & Bioconjugates

Nanoparticle Drug product Formulation and F&F

Innovative product catalog





WE DEVELOP & MANUFACTURE PRECISION POLYMERS, LIPID EXCIPIENTS, CONJUGATES & OPTIMIZED NANOPARTICLE FORMULATIONS

that are scalable to support small and large-scale cGMP manufacturing volumes.

Complete Assistance along your path to Market Authorization



CDMO END-TO-END Services

Preclinical Development

From discovery to preclinical, we support early-stage development

- Process development
- Formulation screening
- Pilot batch manufacturing for non-clinical and GLP tox studies
- Analytical method development

Clinical Supply

Accelerating your path to clinic — from candidate optimization to GMP production.

We enable smooth progression toward IND filing for novel excipients, drug substances, and drug products.

- Clinical supply of investigational products
- Fill & Finish
- Process & Method validation
- Quality by Design
- Regulatory support for clinical trial submissions

Commercial Manufacturing

From late-stage development to global market launch, we deliver quality at scale. We offer fully integrated GMP manufacturing with regulatory support to ensure timely, compliant, and reliable supply.

- Commercial batch release
- End-to-end tech transfer, scale-up & commercial readiness
- Regulatory support for NDA/BLA submissions across major markets

Paving the Future of Medicine

CDMO partner of choice enabling next-generation therapies from concept to cure

	Disease	*Preclinical*	*Phase I*	*Phase II*	*Phase III / Pivotal*	*Market Approval & Commercial supply*
Customer 1 EU	Duchenne Muscular Dystrophy	→	→	→	→	
Customer 2 NA	Bladder Cancer	→	→	→	→	
Customer 3 NA	Wilson Disease	→	→	→		
Customer 4 NA	Hunter Syndrome	→	→	→		
Customer 5 EU	Unresectable Malignant Melanoma	→	→	→		
Customer 6 EU	ALS (ELA)	→	→			
Customer 7 NA	Surgery-trauma Microbial infection	→	→			
Customer 8 EU	UCI Sepsis	→	→			
.....						
Customer X EU	Solid Tumors	→				
Customer X EU	Medical Device : eye disorder	→				



GMP PRODUCTION SITE

Av. Benjamín Franklin, 19
46980 Paterna, Valencia, Spain



Carrer d'Alexander Graham Bell, 6
46980 Paterna, Valencia, Spain

INNOVATION & DEVELOPMENT SITE



COMMERCIAL OFFICE

One Broadway, 14th floor
02142, Cambridge, MA, US

2012-2017

- **Founded in 2012** - CIPF
- Investment From Columbus Venture Partners
- QA/QC departments established
- GLP Certification obtained



CIPF

COLUMBUS VENTURE PARTNERS

2018-2019



- 27,000 sq ft GMP Clinical Drug Substance facility
- Two GMP Suites Qualified for Drug Substance Mfg.
- First 2 GMP products released

2020-2021

- Aseptic Fill/Finish GMP suits installed
- Acquired by Arcline Investment Management



ARCLINE
INVESTMENT MANAGEMENT

2022-2023



- Expanded lipid & polymer Nanoparticle formulation capacity
- 50+ cGMP Drug Substance batches produced/ released
- **AEMPS** Accreditation for GMP Manufacturing of Drug Products for clinical trials
- 30,000 sq ft building **Innovation Center**

2024

- **Commercial GMP** area qualified for Excipient & Drug Substance Manufacturing area
- Third clinical GMP suit qualified for Excipient & Drug Substance Manufacturing



12+ years developing advanced drug delivery solutions

Bring your customer experience to the next level

We care

We develop our people.
We are customer centric.
We respect our suppliers.
Always with patients in mind

We never give up

We think put of the box,
we design, test, adapt and
continously improve

We welcome problems

We strive for scientific innovation
and operational excellence
to create value in the market

+50
Customers worldwide

+100
FTEs
+60% women

Supporting
+15
Ongoing Clinical Programs

2
Life changing therapies (FDA license ongoing)

+93%
On time in Full

+200
Batches manufactured

61
Customer NPS
Industry average <20

We are proud to solve problems and to receive outstanding testimonies from our Customers

61

Customer NPS
Industry average <20

9.2 AAA

Most Reviewed CDMO

Best Lipid nanoparticles formulation supplier

Best Lipid Excipient Supplier

SciRank
Make Informed Decisions

Macro Biologics

"Curapath has proven itself to be a **capable and reliable partner**. Over the past four years we have been repeatedly impressed by their knowledge and professionalism. The Curapath team has been both **skilled and responsive to our needs**, as well as innovative in meeting new challenges. Simply stated, Curapath has brought **real value** to our programs and to our company. We look forward to the next phases of our relationship"

DANIEL J. HUANG & MICHAEL BEVILACQUA

Vice President of Operations & MD., PhD. – CEO, CSO, Director & Co-Founder on Macro Biologics

"We only have a small project with Curapath, but communication from the BD team and project manager have always been impeccable. They are easy and quick to understand what I as a customer want and need, they come up with proposals and solutions, they are always responsive, super friendly, and well-prepared for our regular meetings - it's a breeze and makes my life so much easier. The R&D team works diligently, with proper care of the product, and the holistic project strategy in mind, and wherever appropriate, make smart recommendations for strategy adaptations or additional tests to ensure maximum outcome for the customer."

Senior Development Manager – Generic Pharma Company, Europe

BioDevek

"We are fortunate to have Curapath as our partners for the scale-up process of our adhesive hydrogel technology. They **consistently provided high-quality materials and quickly adapted to new product requirements**, all while maintaining the **highest degree of quality and scientific rigor**."

GONZALO MUÑOZ TABOADA, M.S., MBA

CEO, BioDevek Inc.

UCLA

"I have been fortunate to work with Curapath on a number of projects where they have been an excellent partner as a CMO and fantastic team members in research and development activities.

Having worked within the polypeptide field for more than 25 years, I have seen and been involved with many efforts to commercialize these specialty polymers. In my view, Curapath has **achieved a depth of understanding** and a **level of expertise** in polypeptide manufacturing and analytics that is **second to none**.

I see Curapath as a **tremendous asset**..., and **highly recommend them** as a valuable resource for all polypeptide manufacturing needs."

PROFESSOR TIM J. DEMING, BIOENGINEERING

Chemistry & Biochemistry, University of California Los Angeles

Why Curapath is the right partner

Technical expertise

Specific excellence in polymer and lipid chemistry and PNP / LNP formulation, process development and optimization, GMP manufacturing, strong expertise in characterization and analytical methods development

Track record in significant cost reduction through different approaches (DOE, continuous process optimization, streamlined supply chain…).

Strong supply chain management: Double sourcing of raw materials, logistics.

World-class Project Management

Effective planning, execution, monitoring and control of projects to achieve desired OTIF execution. Focused on continuous improvement, and delivering value to stakeholders.

Communication and collaboration: Effective communication is an essential part of our DNA. We foster open dialogue and communication throughout the development process, as well as open collaboration with all the stakeholders involved.

Flexibility, agility and proactiveness: Our experience enables us to anticipate pitfalls, being adaptable to changing project requirements or timelines, accommodating needs as they evolve.

Reputation and references

“Satisfied customers are our best salespeople”. Despite being a relatively young company, we have developed **one of the strongest reputations in the industry,** supported by our **track record** and **outstanding feedback** from partners and customers. They can provide insights into our **reliability and performance.**

Quality & Regulatory


Robust Quality Assurance System: Proven history of maintaining high-quality standards through testing and validation processes.


Regulatory Compliance: Strong track record of compliance with the most relevant regulatory standards (FDA, EMA) and certifications (cGMP).

GMP Manufacturing capabilites

Manufacturing of Lipid, Polymers & Bioconjugates


Nanoparticle Drug product Formulation and F&F











WE PROVIDE END-TO-END GMP MANUFACTURING CAPABILITIES FOR POLYMERS, LIPIDS & NANOPARTICLES,

supporting your programs from early development to commercial-scale production with full regulatory compliance.

Complete Assistance along your path to Market Authorization



CDMO END-TO-END Services

	Custom Synthesis & Formulation	Analytics	Regulatory
Preclinical Development	• Discovery and process development support • Tech transfer & Gap analysis • Robust, scalable process optimization • HTS platform for polymer/lipid nanoparticle • Pilot batch manufacturing for non-clinical and GLP tox studies	• Analytical method implementation • Method development & testing • Formulation & characterization • Pre-stability and forced degradation studies	
Clinical Supply	• Process development & optimization for polymer and lipid excipients • CPP & PAR • Clinical supply, QP batch certification, and release of investigational medicinal products	• Method validation & process characterization • Quality by Design • ICH-compliant stability studies	• Regulatory support for clinical trial submissions • IND / IMPD-enabling data packages
Commercial Manufacturing	• End-to-end tech transfer, scale-up & commercial readiness • Double sourcing strategy & project derisking	• Process & method validation • Full process characterization and impurity clearance • ICH stability studies & commercial batch release	• Regulatory support for NDA/BLA submissions across major markets

Curapath is a one-stop-shop for Polymers, Lipids & Nanoparticle formulation, and covers all steps from preclinical to commercial phase

Clinical, Product and Process Development lifecycle

Clinical Development Phases



Product and Process Development Stages



QbD Risk Assessments and Milestones



1. Target Product Profile (TPP) identification
2. Quality Target product profile (QTTP) definition
3. Critical quality Attributes (CQA) risk assessment
4. Initial process risk assessment (pCPPs)
5. Process risk assessment 2
6. Design space definition
7. Control Strategy risk assessment
8. Control strategy definition
9. Ongoing improvement and support

ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological entities)

GMP manufacturing capabilities of polymer and lipid-based therapeutics



POLYMER & POLYMER-LIPID EXCIPIENT Manufacturing

Our company provides proven scale-up capabilities, analytical development and a comprehensive CMC package, including:

- Preclinical Development
- Technology Transfer
- GMP Manufacturing
- Drug Product Formulation, Fill & Finish services to support clinical development
- Method Development, Validation and ICH stability studies
- CMC Regulatory support for IND & BLA submission

PARAMETER	LIMITS	RESULTS			
Batch		E01	E02	F01	F02
Quality Grade		Nonclinical	cGMP	cGMP	cGMP
Batch Size		1 Kg	2 Kg	2 Kg	2 Kg
RELEASE					
Physical & Chemical Data					
Appearance	Solid	Solid	Solid	Solid	Solid
Color	White to off-white	White	White	White	White
Analytical Quality					
Identity by ATR-FTIR	Conforms to structure	Conforms	Conforms	Conforms	Conforms
Purity by SEC (in anhydrous basis)	97.0 – 103.0 %	98.7 %	97.8 %	101.9 %	102.5 %
Molecular Weight (kDa) (Mw) by SEC	18.2 - 24.6 kDa	21.5 kDa	21.5 kDa	21.0 kDa	22.7 kDa
Polydispersity Index (Mw/Mn) by SEC	< 1.20	1.01	1.01	1.01	1.01
Counterion by IC (% w/w)	14.0 – 20.0 %	17* %	17.7 %	16.0 %	16.0 %
Water content by KF (% w/w)	< 10.0 %	4.6 %	3.1 %	1.7 %	1.9 %
Lipid-Polymer Ratio Ratio by HPLC-MS	2.5 - 4.0	3.1	3.1	2.9	2.8
Polymer enantiomeric excess by HPLC-MS	≥ 95 %	98 %	99 %	99 %	98 %
Impurities					
Impurity 1 GC-FID (% w/w)	< 0.50%	0.6 %**	0.1 %	0.2 %	0.1 %
Impurity 2 GC-FID (% w/w)	< 0.30 %	< LOD	< 0.02 %	< LOD	< 0.02 %
Impurity 3 GC-FID (% w/w)	< 0.088 %	< LOD	< 0.02 %	< LOD	< LOD
Impurity 4 by IC (% w/w)	< 0.30 %	< 0.05 %	< 0.05 %	< LOD	< 0.05 %
Organic related substances					
Substance 1 by IC (% w/w)	< 0.30 %	< LOD	< LOD	< LOD	< LOD
Substance 2 by IC (% w/w)	< 0.30 %	< LOD	< LOD	< LOD	< LOD
Substance 3 by IC (% w/w)	< 0.30 %	< LOD	< LOD	< LOD	< LOD
MicroBiological Data					
Total Aerobic Microbial Count (CFU/g)	< 100 CFU/g	< 10 CFU/g	< 10 CFU/g	< 10 CFU/g	< 10 CFU/g
Total Yeast and Molds Count (CFU/g)	< 100 CFU/g	< 10 CFU/g	< 10 CFU/g	< 10 CFU/g	< 10 CFU/g
Endotoxin (EU/g)	< 75 EU/g	< 50 EU/g	< 50 EU/g	< 75 EU/g	< 75 EU/g


GMP CERTIFIED

0,5-10/kg batch

+200 GMP batches Manufactured
+200 Non-Compendial Methods Validated
100% Batch release compliance

Our Technologies

Complete set of technologies to accelerate clinical development and go-to-market strategies



	Lab	Tech batch	GMP clinical & commercial
Manufacturing			
Non-GMP reactors up to 50 L	√	√	
GMP reactors for Drug Substance up to 100 L			√
GMP Reactors for Drug Product Formulation up to 100 L			√
Downstream			
TFF / Tangential Flow Filtration (Cassettes, hollow fiber) up to 15L	√	√	√
Flash Chromatography	√	√	√
High Pressure Preparative Chromatography	√	√	√
Crystallization / Precipitation	√	√	√
Lyophilization Drug Substance	√	√	√
Lyophilization Drug Product	√	√	**Established Partnership**
Knauer mixing device for LNP / PNP	√ **HTS**	√	√
Fill & Finish capabilities up to 1500 vials / batch		√	√
Sterile filtration	√	√	√
Analytics			
Analytical methods development and validation (HPLC/MS, HPLC/CAD, SEC-MALS-RI, SLS, IC, KF, ATR-FTIR...)		√	
Stability studies / ICH guidelines		√	
Compatibility studies		√	
Particle characterization (CE, qPCR, Fluorescence, PSD Malvern, DLS, Zpot, UV-Assay, LC)		√	
In vitro testing (cells bank: liver, kidney, ...)		√	
In vivo testing / Tox studies		**Established Partnership**	

From concept to reality : our Packaged Formulation Screening services accelerate nanoparticles formulation

Polymer Nanoparticle Formulations

Work Package	ESSENTIAL	ADVANCED	EXPERT
Synthesis Feasibility Study	2 Complexing Polymers + 1 Shielding Polymer	3 Complexing Polymers + 1 Shielding Polymer	4 Complexing Polymers + 1 Shielding Polymer
Formulation Development	Screening of 15-20 Formulations	Screening of 30 Formulations	Screening of 40 Formulations
Stability Study	2 Samples	3 Samples	4 samples
In Vitro Study	Not included	Not included	Included with reporter gene

All Packages can be Customised according to your project specific needs

Six to Twelve weeks to take your PNP formulations from concept to reality

Your quote, delivered in less than 24 hours



Lipid Nanoparticle Formulations

Work Package	ESSENTIAL	ADVANCED	EXPERT
Lipid Sourcing	i-lipids, Helper lipids, Shielding Lipids	i-lipids, Helper lipids, Shielding Lipids	i-lipids, Helper lipids, Shielding Lipids
Formulation Development	Screening of 10 Formulations	Screening of 15 Formulations	Screening of 20 Formulations
Stability Study	2 Samples	3 Samples	4 samples
In Vitro Study	Not included	Not included	Included with reporter gene



All Packages can be Customised according to your project specific needs

Six weeks to take your LNP formulations from concept to preclinical

Your quote, delivered in less than 24 hours

Services also available for:

- Liposomal formulations
- PLA-PLGA nanoparticles
- Protein-based nanoparticles
- Metal-based particles coating
- Targeted nanoparticles


Multiple Paylaods



Peptides




Nucleic Acids



Small molecules

Harnessing High-Throughput Technologies for Rapid Screening and Optimization of LNP Formulations

Polymer Nanoparticles (PNP)



DoE



Automated Pumps



IJM


T-Mixer

Microfluidics


Lipid Nanoparticles (LNP)







Buffer Exchange & Concentration



+200
formulations/ Week

+50
In vitro testing/week

FAST
Formulation Optimization

FAST
Mixing Process Development

Seamless LNP formulation screening, process development and GMP manufacturing through a vertically integrated IJM platform



- Seamless Tech transfer from alternative mixing technologies
- Nanoparticle formulation Development
- Formulation Process Characterization & Scale-up
- GMP production to support clinical trias
- Vertically integrated platform, like-for-like to comercial manufacturing

Our Aseptic Filling operations are ideal for Gene and Cell Therapies and Orphan Drug trials.



Aseptic Fill/Finish



Flexible formats:

SEMIMANUAL FILLING LINE

- 2-20R Vials, up to 1500 vials/Batch
- *100-500mL Bottles*
- *1-5L Bags*

AUTOMATED LINE *(through qualified partner network:*

- *Up to 10.000 liquid vials/batch, 2R, 10R, 20R, 50R*
- *Up to 4.000 lyophilized vials/batch (for 10R)*

Environmental Monitoring, Sterility Assurance & Qualified Person release

Bulk Formulation up to 50L batch (Bioburden reduction available for shipment to Third parties F&F)

Innovative Products

Novel Polymer & Lipid Excipients

Innovative product catalog

Catalog polymers

- API / Peptide encapsulation & Conjugation
- Non-viral DNA delivery
- Solubilizer
- Biomaterials for medical devices


Innovative Lipids :

- Proprietary shielding lipids
- PEG replacement
- Targeting LNP delivery – moiety attachment
- Ionizable lipids library

Ready-to-use LNP formulations

- Industry standard formulations
- Formulations using propietary technologies

Featured Products



Our curated selection of products to boost your drug delivery strategies includes:

- **High-performance ionizable lipids**, ideal for mRNA and nucleic acid delivery.
- **Stealth polymers and shielding components** (PSar, PGA) to enhance circulation time and reduce immunogenicity.
- **Functionalized polymers (**Mal, COOH, N_3) ready for conjugation with antibodies, peptides, or other targeting ligands.
- Key **building blocks for polymeric nanoparticles** (PNPs), including polyelectrolytes and PGA/PLys derivatives.
- **Available in R&D and GMP grades**, with rapid shipping from 100 mg to multi-gram quantities.
- **Custom synthesis and scale-up support**, from early development to full GMP manufacturing.

Designed to support cutting-edge applications in mRNA therapeutics, oncology, and targeted drug delivery.

Polymers toolbox


Off-the-shelf products and building blocks

	Applications	*IP*	*R&D*	*Tech batch*	*GMP clinical*	*GMP commercial*	*Scale*
Poly-Imine and transfection reagents	1. Nucleic acid delivery 2. Bioproduction	N/A					kg
Polyglutamate & derivatives	1. Shielding 2. Conjugation 3. PEG replacement	Public patent					kg
Polylysine	1. Encapsulation 2. Conjugation	N/A					kg
Polyoxazoline	1. Particle delivery 2. Medical devices 3. Tissue eng.	Patent					kg
Polysarcosine	1. Shielding lipid 2. PEG replacement	Public patent					kg
Complexing Polymer STAR	1. DNA delivery 2. Conjugation	Public patent					100g-kg
Oleyl-PSar	1. Solubilizer	Public patent					100g-kg
.....							
Poly amino acids	1. Multiple uses	N/A					100g-kg
PBAES	1. Multiple uses	N/A					100g-kg
PMMAs	1. Multiple uses	N/A					100g-kg
.....							


.....And more

Curapath's Ionizable Polymer Toolbox For Non-viral Nucleic Acid Delivery

- Increased Nanoparticle stability
- Chemical versatility
- Easy to decorate for targeting extrahepatic tissues
- Lower production costs
- Flexible cargo capacity
- Less IP restrictions



Curapath's complexing polymers outperform benchmark in terms of transfection efficiency



PATENTED

IONISABLE/CATIONIC POLYMER



- Nucleic acid interaction
- Endosomal escape
- Transfection efficiency (Specially N.A. to be delivered in nucleous e.g. DNA, Gene Editing)

NUCLEIC ACID PAYLOAD



- Encodes protein of interest to be translated by a target cell


SHIELDING POLYMER



- Prevents off-target toxicities
- Avoids particle aggregation
- Improves PK

* Screening results in patient selected cell line (primary cells). Unshielded PXs formulated in water @150ng DNA. N/P=30 for Curapath's complexing, N/P=5 for benchmark

Beyond PEGylated lipids: Non-immunogenic shielding lipids in LNP vaccines



Ionizable Lipid *(neutral/protonated)*
Aids in the encapsulation of nucleic acids through electrostatic interactions

'Helper' Lipid
Improves LNP stability and fusogenicity

PEG-Lipid
Prevents non-specific protein absorption, particle aggregation and controls LNP size


Nucleic Acid *(e.g. mRNA)*
Encodes protein of interest


Cholesterol
Decreases permeability of the LNP and enhances its stability

PEG Alternatives


PAOx, PSar, PGA-Diol, Biocompatible, overcome PEG immunogenicity

Tetradecylamine-PGADiol






PAOx-based Lipid



PSar-succ-tocopherol

.....And more in our catalogue

Beyond Pegylated Lipids: Non-immunogenic Shielding Lipids In Vaccines



PEG-Lipid


Prevents non-specific protein absorption, particle aggregation and controls LNP size. Immunogenicity concerns.

PEG Alternatives




IN VITRO TESTING (DENDRITIC CELLS)


DCs % GFP



MFI




Cell Viability



LNP DMG-PEG LNP Curapath's shielding lipid

IN VIVO I.M. TESTING (PROTEINEXPRESSION)

ELISA



ADDED VALUE VS PEG

- Biocompatible & Endogenous building blocks
- Overcome PEG immunogenicity
- Similar in-vivo performance (transfection efficiency, safety).

MANUFACTURING FEASIBILITY

- Curapath's shielding lipids have been synthesized and **scaled-up with batch-to-batch** reproducibility.

GMP PRODUCTION

- **GMP manufacturing** of polymer-lipids in GMP multi-gran scale at Curapath's plant.


STRONG PATENT PROTECTION

- Excellent patent position overcoming PEG components.
- Priorities from 2021/2022 & national phases 2024. Expected worldwide protection through 2041/2042.

LNP FORMULATIONS

- Curapath's shielding lipid yield NPs with adequate size in the 100 nm range and low PDIs, with >90% nucleic acid encapsulation efficiency.

Ready-to-Use LNP formulations, FTO



Ionizable Lipid *(neutral/protonated)*
Aids in the encapsulation of nucleic acids through electrostatic interactions

PEG Alternatives
PAOx, PSar, PGA-Diol, Biocompatible, overcome PEG immunogenicity






Figure 11. Quantification of *in vivo* luminiscence results obtained with a panel of different Certest ionizable lipids formulated with Curapath's Shielding Lipids. Luminescence was measured 4 hours after intramuscular injection of 1 µg of Fluc mRNA/mouse.



Sizes 80-150 nm, PDI < 0.2, EE > 99%




Biodistribution in mice

- Available i-lipid library with FTO
- PEG vs. non-PEG lipids
- Good Manufacturability, GMP production established, CMC package available.
- Increased in vivo expression vs. Spikevax, Comirnaty or Onpattro formulations.
- Reduced toxicity with no hepatotoxicity signs

certest

CURAPATH



Novel Components to Power the Next Generation of Gene Therapies

GMP CERTIFIED

Tailored Development Workflows Built for delivery Success



Quality-Driven Manufacturing, Designed to Scale



Your Vision, Accelerated (more than a service provider we act as a true innovation partner)

Your CDMO Partner for Drug Delivery Programs



8 to 10 September 2025

Valencia, Spain


NanoThera SUMMIT 2025


PIONEERING DRUG DELIVERY & GENE THERAPY





nanotherasummit.com

Brochures, Product Catalogue, Case Studies, Product Highlights, App Notes, Blog, Posters…..










… and more to come

www.curapath.com



Vicent Nebot (CTO) vnebot@curapath.com

Carles Felip (Head of BD) cfelip@curapath.com

Frederic Schab (CCO) fschab@curapath.com

EMAIL info@curapath.com **PHONE** (+34) 963.769.080 **WEB** www.curapath.com